Anti-fibrotic effects of the IP receptor agonist

Anti-fibrotic effects of the prostacyclin receptor (IP receptor) agonist in patients with pulmonary arterial hypertension associated with systemic sclerosis

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1011210052

Enrollment

Registered

2021-11-26

Start date

2021-11-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pulmonary arterial hypertension associated with systemic sclerosis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Males and females aged 18 or more 2. Needs to be treated with selective pulmonary vasodilators 3. Capable of giving signed informed consent

Exclusion criteria

Exclusion criteria: 1. Lactating or pregnant females 2. Strongly suspected of structural brain abnormality 3. Unable to undergo the proper procedure of chest CT 4. Needs to be treated with anti-fibrotic drugs 5. Prior or current receipt of anti-fibrotic drugs 6. Inappropriate in the option of the Investigator

Design outcomes

Primary

Measure	Time frame
The change in normal lung volume or fibrotic lung volume from baseline () to week 52, determined by quantitative chest CT : 12 or less week before the administration of selexipag	—

Contacts

Public ContactMasaru Kato

Hokkaido University Hospital

ktmasaru@med.hokudai.ac.jp+81-11-706-5916

Outcome results